Polaryx Therapeutics, Inc. Common Stock (PLYX)

• Market cap: $422M
• 1 day: -44.31%
• 5 days: -80.2%
• 1 month: -74.54%
• 3 months: -74.54%
• 6 months: -74.54%
• Year to date: -74.54%
• 1 year: -74.54%
• 5 years: -74.54%
• 10 years: -74.54%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small molecule drug candidates designed to address core pathological mechanisms common to LSDs.